Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | PKM | P14618 | 2/20 | 0.44 |
| ▸ | CA2 | P00918 | 12/20 | 0.43 |
| ▸ | CA1 | P00915 | 10/20 | 0.43 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.41 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.41 |
| ▸ | CA9 | Q16790 | 9/20 | 0.41 |
| ▸ | CA12 | O43570 | 9/20 | 0.41 |
| ▸ | CA7 | P43166 | 6/20 | 0.41 |
| ▸ | CA14 | Q9ULX7 | 6/20 | 0.41 |
| ▸ | CA4 | P22748 | 5/20 | 0.41 |
| ▸ | CA6 | P23280 | 5/20 | 0.41 |
| ▸ | CA5A | P35218 | 5/20 | 0.41 |
| ▸ | CA5B | Q9Y2D0 | 5/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4231613 | 0.85 | CA2 (0.51) | LMNAPKMCA2CA1CA9 | |
| SCHEMBL3795489 | 0.81 | ALDH1A1 (0.43) | LMNACA2CA1CA12CA7 | |
| SCHEMBL25270499 | 0.81 | ALDH1A1 (0.35) | LMNAPKMCA2CA12KDM4E | |
| SCHEMBL6742234 | 0.81 | PTGS2 (0.42) | LMNAPKMCA2PTGS2CA12 | |
| SCHEMBL3800834 | 0.77 | CA2 (0.42) | CA2CA1CA9CA12 | |
| SCHEMBL25511714 | 0.77 | ALDH1A1 (0.43) | LMNAPKMCA2CA12KDM4E | |
| SCHEMBL9839080 | 0.74 | LMNA (0.82) | LMNAPKMCA2CA1CA9 | |
| SCHEMBL29469339 | 0.73 | CYP2A6 (0.43) | CA2CA1CA9CA12CA7 | |
| Benzothiophene SCHEMBL28873595 | 0.69 | CA2 (0.46) | LMNACA2CA1CA9CA12 | |
| SCHEMBL7213512 | 0.69 | MEN1 (0.38) | PKMCA2CA12KDM4EMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090118323-A1 | ANTITUMOR BENZOYLSULFONAMIDES | MADER MARY MARGARET | 2009-05-07 | — | — | US | disclosed |
| EP-1565438-B1 | ANTITUMOR BENZOYLSULFONAMIDES | LILLY CO ELI (US) | 2007-10-17 | — | — | EP | disclosed |
| US-7282595-B2 | Antitumor benzoylsulfonamides | ELI LILLY AND COMPANY (US) | 2007-10-16 | — | — | US | disclosed |
| US-20060106053-A1 | Antitumor benzoylsulfonamides | ELI LILLY AND COMPANY | 2006-05-18 | — | — | US | disclosed |
| EP-1565438-A1 | ANTITUMOR BENZOYLSULFONAMIDES | ELI LILLY AND COMPANY (US) | 2005-08-24 | — | — | EP | disclosed |
| WO-2004048329-A1 | ANTITUMOR BENZOYLSULFONAMIDES | ELI LILLY AND COMPANY (US) | 2004-06-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090118323-A1 | ANTITUMOR BENZOYLSULFONAMIDES | HCCS, GLS2, GLS | LMNA 2979/4885PKM 1703/4885CA2 1594/4885 |
| US-20060106053-A1 | Antitumor benzoylsulfonamides | HCCS, GLS2, GLS | LMNA 2979/4885PKM 1703/4885CA2 1594/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.